nodes	percent_of_prediction	percent_of_DWPC	metapath
Capecitabine—Pleural disorder—Riluzole—amyotrophic lateral sclerosis	0.052	0.0619	CcSEcCtD
Capecitabine—CES1—Phase I biotransformations, non P450—PON1—amyotrophic lateral sclerosis	0.0319	0.2	CbGpPWpGaD
Capecitabine—Personality change—Riluzole—amyotrophic lateral sclerosis	0.0256	0.0304	CcSEcCtD
Capecitabine—Angina unstable—Riluzole—amyotrophic lateral sclerosis	0.0194	0.0231	CcSEcCtD
Capecitabine—Hypoaesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.0188	0.0224	CcSEcCtD
Capecitabine—Facial paralysis—Riluzole—amyotrophic lateral sclerosis	0.0154	0.0183	CcSEcCtD
Capecitabine—Trismus—Riluzole—amyotrophic lateral sclerosis	0.0147	0.0175	CcSEcCtD
Capecitabine—Gastrointestinal tract irritation—Riluzole—amyotrophic lateral sclerosis	0.0137	0.0163	CcSEcCtD
Capecitabine—CES1—E2F transcription factor network—UXT—amyotrophic lateral sclerosis	0.0122	0.0765	CbGpPWpGaD
Capecitabine—VIIth nerve paralysis—Riluzole—amyotrophic lateral sclerosis	0.012	0.0142	CcSEcCtD
Capecitabine—Paraesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.0105	0.0124	CcSEcCtD
Capecitabine—Proctalgia—Riluzole—amyotrophic lateral sclerosis	0.0105	0.0124	CcSEcCtD
Capecitabine—Pneumothorax—Riluzole—amyotrophic lateral sclerosis	0.00986	0.0117	CcSEcCtD
Capecitabine—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00959	0.0114	CcSEcCtD
Capecitabine—TYMS—E2F transcription factor network—UXT—amyotrophic lateral sclerosis	0.00845	0.0531	CbGpPWpGaD
Capecitabine—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00844	0.01	CcSEcCtD
Capecitabine—DPYD—Nucleotide metabolism—GSR—amyotrophic lateral sclerosis	0.00842	0.053	CbGpPWpGaD
Capecitabine—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.00825	0.00981	CcSEcCtD
Capecitabine—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.00816	0.0097	CcSEcCtD
Capecitabine—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00772	0.00918	CcSEcCtD
Capecitabine—Respiratory distress—Riluzole—amyotrophic lateral sclerosis	0.00772	0.00918	CcSEcCtD
Capecitabine—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00764	0.00909	CcSEcCtD
Capecitabine—CDA—Nucleotide metabolism—GSR—amyotrophic lateral sclerosis	0.00751	0.0472	CbGpPWpGaD
Capecitabine—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00749	0.0089	CcSEcCtD
Capecitabine—Intestinal obstruction—Riluzole—amyotrophic lateral sclerosis	0.0072	0.00856	CcSEcCtD
Capecitabine—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.00713	0.00848	CcSEcCtD
Capecitabine—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00706	0.0084	CcSEcCtD
Capecitabine—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00706	0.0084	CcSEcCtD
Capecitabine—Ileus—Riluzole—amyotrophic lateral sclerosis	0.00693	0.00824	CcSEcCtD
Capecitabine—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00693	0.00824	CcSEcCtD
Capecitabine—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00687	0.00817	CcSEcCtD
Capecitabine—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00681	0.00809	CcSEcCtD
Capecitabine—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.00663	0.00788	CcSEcCtD
Capecitabine—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00641	0.00762	CcSEcCtD
Capecitabine—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00641	0.00762	CcSEcCtD
Capecitabine—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.0063	0.00749	CcSEcCtD
Capecitabine—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.0061	0.00726	CcSEcCtD
Capecitabine—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.00606	0.0072	CcSEcCtD
Capecitabine—TYMP—Nucleotide metabolism—GSR—amyotrophic lateral sclerosis	0.006	0.0377	CbGpPWpGaD
Capecitabine—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00596	0.00709	CcSEcCtD
Capecitabine—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00547	0.0065	CcSEcCtD
Capecitabine—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.00543	0.00646	CcSEcCtD
Capecitabine—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.0054	0.00642	CcSEcCtD
Capecitabine—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00529	0.00629	CcSEcCtD
Capecitabine—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00519	0.00617	CcSEcCtD
Capecitabine—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00519	0.00617	CcSEcCtD
Capecitabine—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00519	0.00617	CcSEcCtD
Capecitabine—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00515	0.00613	CcSEcCtD
Capecitabine—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00503	0.00598	CcSEcCtD
Capecitabine—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.005	0.00594	CcSEcCtD
Capecitabine—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00497	0.00591	CcSEcCtD
Capecitabine—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00491	0.00583	CcSEcCtD
Capecitabine—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00491	0.00583	CcSEcCtD
Capecitabine—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00491	0.00583	CcSEcCtD
Capecitabine—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.00488	0.0058	CcSEcCtD
Capecitabine—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00479	0.0057	CcSEcCtD
Capecitabine—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00474	0.00563	CcSEcCtD
Capecitabine—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00474	0.00563	CcSEcCtD
Capecitabine—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00468	0.00557	CcSEcCtD
Capecitabine—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00466	0.00554	CcSEcCtD
Capecitabine—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00444	0.00527	CcSEcCtD
Capecitabine—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00444	0.00527	CcSEcCtD
Capecitabine—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00426	0.00506	CcSEcCtD
Capecitabine—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00426	0.00506	CcSEcCtD
Capecitabine—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00417	0.00496	CcSEcCtD
Capecitabine—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.00413	0.00492	CcSEcCtD
Capecitabine—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00409	0.00487	CcSEcCtD
Capecitabine—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00409	0.00487	CcSEcCtD
Capecitabine—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00408	0.00485	CcSEcCtD
Capecitabine—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00406	0.00482	CcSEcCtD
Capecitabine—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00398	0.00473	CcSEcCtD
Capecitabine—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00398	0.00473	CcSEcCtD
Capecitabine—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00384	0.00457	CcSEcCtD
Capecitabine—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00379	0.00451	CcSEcCtD
Capecitabine—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00379	0.00451	CcSEcCtD
Capecitabine—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00377	0.00449	CcSEcCtD
Capecitabine—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00376	0.00447	CcSEcCtD
Capecitabine—TYMS—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00376	0.0236	CbGpPWpGaD
Capecitabine—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00374	0.00445	CcSEcCtD
Capecitabine—Purpura—Riluzole—amyotrophic lateral sclerosis	0.0037	0.00439	CcSEcCtD
Capecitabine—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00366	0.00436	CcSEcCtD
Capecitabine—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00365	0.00434	CcSEcCtD
Capecitabine—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00358	0.00425	CcSEcCtD
Capecitabine—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00356	0.00424	CcSEcCtD
Capecitabine—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00356	0.00424	CcSEcCtD
Capecitabine—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00356	0.00424	CcSEcCtD
Capecitabine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00353	0.0042	CcSEcCtD
Capecitabine—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00351	0.00417	CcSEcCtD
Capecitabine—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00344	0.00409	CcSEcCtD
Capecitabine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00339	0.00403	CcSEcCtD
Capecitabine—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00339	0.00403	CcSEcCtD
Capecitabine—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00337	0.00401	CcSEcCtD
Capecitabine—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00335	0.00398	CcSEcCtD
Capecitabine—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00331	0.00394	CcSEcCtD
Capecitabine—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00329	0.00391	CcSEcCtD
Capecitabine—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00325	0.00387	CcSEcCtD
Capecitabine—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00324	0.00385	CcSEcCtD
Capecitabine—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00322	0.00383	CcSEcCtD
Capecitabine—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00321	0.00381	CcSEcCtD
Capecitabine—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00315	0.00375	CcSEcCtD
Capecitabine—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00314	0.00374	CcSEcCtD
Capecitabine—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00314	0.00374	CcSEcCtD
Capecitabine—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.0031	0.00368	CcSEcCtD
Capecitabine—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00308	0.00366	CcSEcCtD
Capecitabine—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00308	0.00366	CcSEcCtD
Capecitabine—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00308	0.00366	CcSEcCtD
Capecitabine—TYMS—Nucleotide metabolism—GSR—amyotrophic lateral sclerosis	0.00307	0.0193	CbGpPWpGaD
Capecitabine—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.003	0.00357	CcSEcCtD
Capecitabine—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00296	0.00352	CcSEcCtD
Capecitabine—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00295	0.00351	CcSEcCtD
Capecitabine—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00292	0.00348	CcSEcCtD
Capecitabine—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00288	0.00342	CcSEcCtD
Capecitabine—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00288	0.00342	CcSEcCtD
Capecitabine—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00281	0.00334	CcSEcCtD
Capecitabine—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.0028	0.00333	CcSEcCtD
Capecitabine—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00331	CcSEcCtD
Capecitabine—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00276	0.00328	CcSEcCtD
Capecitabine—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00274	0.00326	CcSEcCtD
Capecitabine—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00274	0.00326	CcSEcCtD
Capecitabine—Depression—Riluzole—amyotrophic lateral sclerosis	0.00274	0.00325	CcSEcCtD
Capecitabine—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00271	0.00322	CcSEcCtD
Capecitabine—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00269	0.0032	CcSEcCtD
Capecitabine—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00269	0.0032	CcSEcCtD
Capecitabine—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—amyotrophic lateral sclerosis	0.00269	0.0169	CbGpPWpGaD
Capecitabine—CES1—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00268	0.0168	CbGpPWpGaD
Capecitabine—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00268	0.00318	CcSEcCtD
Capecitabine—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00268	0.00318	CcSEcCtD
Capecitabine—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00267	0.00317	CcSEcCtD
Capecitabine—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00262	0.00311	CcSEcCtD
Capecitabine—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.0026	0.00309	CcSEcCtD
Capecitabine—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00259	0.00308	CcSEcCtD
Capecitabine—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00256	0.00305	CcSEcCtD
Capecitabine—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00251	0.00298	CcSEcCtD
Capecitabine—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00248	0.00294	CcSEcCtD
Capecitabine—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00247	0.00294	CcSEcCtD
Capecitabine—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00246	0.00293	CcSEcCtD
Capecitabine—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00246	0.00293	CcSEcCtD
Capecitabine—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00245	0.00292	CcSEcCtD
Capecitabine—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00245	0.00291	CcSEcCtD
Capecitabine—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00289	CcSEcCtD
Capecitabine—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00289	CcSEcCtD
Capecitabine—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00242	0.00288	CcSEcCtD
Capecitabine—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00242	0.00287	CcSEcCtD
Capecitabine—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00233	0.00277	CcSEcCtD
Capecitabine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00274	CcSEcCtD
Capecitabine—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00229	0.00272	CcSEcCtD
Capecitabine—DPYD—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.00228	0.0143	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—VEGFA—amyotrophic lateral sclerosis	0.00226	0.0142	CbGpPWpGaD
Capecitabine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00266	CcSEcCtD
Capecitabine—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00223	0.00265	CcSEcCtD
Capecitabine—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00222	0.00264	CcSEcCtD
Capecitabine—Chills—Riluzole—amyotrophic lateral sclerosis	0.00221	0.00263	CcSEcCtD
Capecitabine—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.0022	0.00262	CcSEcCtD
Capecitabine—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00259	CcSEcCtD
Capecitabine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00216	0.00257	CcSEcCtD
Capecitabine—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00255	CcSEcCtD
Capecitabine—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00251	CcSEcCtD
Capecitabine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.0021	0.0025	CcSEcCtD
Capecitabine—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00207	0.00247	CcSEcCtD
Capecitabine—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00245	CcSEcCtD
Capecitabine—CDA—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.00203	0.0128	CbGpPWpGaD
Capecitabine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00239	CcSEcCtD
Capecitabine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00199	0.00237	CcSEcCtD
Capecitabine—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00198	0.00236	CcSEcCtD
Capecitabine—CES1—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00196	0.0123	CbGpPWpGaD
Capecitabine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00193	0.0023	CcSEcCtD
Capecitabine—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00229	CcSEcCtD
Capecitabine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00229	CcSEcCtD
Capecitabine—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00228	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.00191	0.012	CbGpPWpGaD
Capecitabine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00225	CcSEcCtD
Capecitabine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00224	CcSEcCtD
Capecitabine—Cough—Riluzole—amyotrophic lateral sclerosis	0.00187	0.00223	CcSEcCtD
Capecitabine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00185	0.0022	CcSEcCtD
Capecitabine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00217	CcSEcCtD
Capecitabine—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00217	CcSEcCtD
Capecitabine—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00217	CcSEcCtD
Capecitabine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00216	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00216	CcSEcCtD
Capecitabine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00215	CcSEcCtD
Capecitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00179	0.0112	CbGpPWpGaD
Capecitabine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00212	CcSEcCtD
Capecitabine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00177	0.0021	CcSEcCtD
Capecitabine—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00208	CcSEcCtD
Capecitabine—Infection—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00207	CcSEcCtD
Capecitabine—Shock—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00205	CcSEcCtD
Capecitabine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00204	CcSEcCtD
Capecitabine—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00204	CcSEcCtD
Capecitabine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00203	CcSEcCtD
Capecitabine—TYMP—Bladder Cancer—TP53—amyotrophic lateral sclerosis	0.00171	0.0107	CbGpPWpGaD
Capecitabine—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.0017	0.00202	CcSEcCtD
Capecitabine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00201	CcSEcCtD
Capecitabine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00198	CcSEcCtD
Capecitabine—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00195	CcSEcCtD
Capecitabine—TYMP—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.00163	0.0102	CbGpPWpGaD
Capecitabine—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00159	0.0019	CcSEcCtD
Capecitabine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00188	CcSEcCtD
Capecitabine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00187	CcSEcCtD
Capecitabine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00186	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.00156	0.0098	CbGpPWpGaD
Capecitabine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00183	CcSEcCtD
Capecitabine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00181	CcSEcCtD
Capecitabine—DPYD—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00151	0.00951	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00151	0.00951	CbGpPWpGaD
Capecitabine—CES1—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.00151	0.00951	CbGpPWpGaD
Capecitabine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0018	CcSEcCtD
Capecitabine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00179	CcSEcCtD
Capecitabine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00178	CcSEcCtD
Capecitabine—Pain—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00178	CcSEcCtD
Capecitabine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00172	CcSEcCtD
Capecitabine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00143	0.0017	CcSEcCtD
Capecitabine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00165	CcSEcCtD
Capecitabine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00165	CcSEcCtD
Capecitabine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00165	CcSEcCtD
Capecitabine—DPYD—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00138	0.0087	CbGpPWpGaD
Capecitabine—CDA—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00135	0.00848	CbGpPWpGaD
Capecitabine—CDA—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00135	0.00848	CbGpPWpGaD
Capecitabine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00153	CcSEcCtD
Capecitabine—DPYD—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00129	0.00809	CbGpPWpGaD
Capecitabine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00149	CcSEcCtD
Capecitabine—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00147	CcSEcCtD
Capecitabine—CDA—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00123	0.00776	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00121	0.00761	CbGpPWpGaD
Capecitabine—CES1—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.0012	0.00753	CbGpPWpGaD
Capecitabine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00142	CcSEcCtD
Capecitabine—CES1—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00118	0.00744	CbGpPWpGaD
Capecitabine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00138	CcSEcCtD
Capecitabine—CDA—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00115	0.00721	CbGpPWpGaD
Capecitabine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00132	CcSEcCtD
Capecitabine—Rash—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00131	CcSEcCtD
Capecitabine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00131	CcSEcCtD
Capecitabine—Headache—Riluzole—amyotrophic lateral sclerosis	0.0011	0.0013	CcSEcCtD
Capecitabine—DPYD—Metabolism—DAO—amyotrophic lateral sclerosis	0.00109	0.00688	CbGpPWpGaD
Capecitabine—CDA—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00108	0.00678	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00108	0.00678	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00108	0.00678	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.00107	0.00674	CbGpPWpGaD
Capecitabine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00124	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.00104	0.00654	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000998	0.00627	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000986	0.0062	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000978	0.00615	CbGpPWpGaD
Capecitabine—CDA—Metabolism—DAO—amyotrophic lateral sclerosis	0.000975	0.00613	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000917	0.00576	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000862	0.00542	CbGpPWpGaD
Capecitabine—TYMS—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.000831	0.00523	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000829	0.00521	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—DAO—amyotrophic lateral sclerosis	0.000779	0.0049	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—GSR—amyotrophic lateral sclerosis	0.000765	0.00481	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000756	0.00475	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—TUBA4A—amyotrophic lateral sclerosis	0.000754	0.00474	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—OPTN—amyotrophic lateral sclerosis	0.000754	0.00474	CbGpPWpGaD
Capecitabine—CDA—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000739	0.00465	CbGpPWpGaD
Capecitabine—CDA—Metabolism—GSR—amyotrophic lateral sclerosis	0.000682	0.00429	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—TUBA4A—amyotrophic lateral sclerosis	0.000674	0.00424	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—OPTN—amyotrophic lateral sclerosis	0.000674	0.00424	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—DCTN1—amyotrophic lateral sclerosis	0.000641	0.00403	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000637	0.00401	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000628	0.00395	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000608	0.00382	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000591	0.00371	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—DCTN1—amyotrophic lateral sclerosis	0.000573	0.00361	CbGpPWpGaD
Capecitabine—CDA—Metabolism—CHAT—amyotrophic lateral sclerosis	0.00056	0.00352	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000551	0.00347	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000551	0.00347	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—GSR—amyotrophic lateral sclerosis	0.000545	0.00343	CbGpPWpGaD
Capecitabine—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000512	0.00322	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000504	0.00317	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000469	0.00295	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000464	0.00292	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000448	0.00281	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000441	0.00277	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000413	0.0026	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—DAO—amyotrophic lateral sclerosis	0.000399	0.00251	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—TP53—amyotrophic lateral sclerosis	0.000383	0.00241	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000357	0.00224	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000343	0.00216	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000338	0.00212	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000326	0.00205	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000318	0.002	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.00031	0.00195	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000303	0.00191	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000302	0.0019	CbGpPWpGaD
Capecitabine—CDA—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000301	0.00189	CbGpPWpGaD
Capecitabine—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000289	0.00182	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000285	0.00179	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—GSR—amyotrophic lateral sclerosis	0.000279	0.00175	CbGpPWpGaD
Capecitabine—CDA—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000277	0.00174	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.00027	0.0017	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—APOE—amyotrophic lateral sclerosis	0.000255	0.00161	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000241	0.00151	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000229	0.00144	CbGpPWpGaD
Capecitabine—CDA—Metabolism—APOE—amyotrophic lateral sclerosis	0.000228	0.00143	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000221	0.00139	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000207	0.0013	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000205	0.00129	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000204	0.00128	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000196	0.00123	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000196	0.00123	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—APOE—amyotrophic lateral sclerosis	0.000182	0.00114	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000175	0.0011	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000159	0.001	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000159	0.001	CbGpPWpGaD
Capecitabine—CDA—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000156	0.00098	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000148	0.000932	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000145	0.000914	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000135	0.00085	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000127	0.000799	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000125	0.000784	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000123	0.000774	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	0.000115	0.000723	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000113	0.000711	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—APOE—amyotrophic lateral sclerosis	9.31e-05	0.000585	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—TP53—amyotrophic lateral sclerosis	8.83e-05	0.000555	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	8.71e-05	0.000548	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	8.04e-05	0.000505	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	7.32e-05	0.00046	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	6.6e-05	0.000415	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.38e-05	0.000401	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.02e-05	0.000379	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.13e-05	0.00026	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.55e-05	0.000223	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.26e-05	0.000205	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	2.68e-05	0.000169	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.84e-05	0.000116	CbGpPWpGaD
